Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

November 10, 2017: By Joan McKenna

Valeant PharmaceuticalsValeant reported Nov. 7 that its Bausch + Lomb/International segment grew 1 percent (2 percent cc) in Q3-2017 year over year and accounted for nearly 57 percent of Valeant’s total revenues.

Valeant’s revenues for the quarter totaled $2.2 billion, down 10 percent year over year. Its net income was $1.3 billion compared with a net loss of $1.22 billion for the same period in 2016.

BauschThe Bausch + Lomb segment’s revenues totaled $1.25 billion in the third quarter, up from $1.24 billion in Q3-2016.

Laval, Quebec-based Valeant also reported that it reduced total debt by about $6 billion since the end of the first quarter of 2016. The company’s current long-term debt is $27.43 billion.

“Valeant is a very different company today than it was a year ago,” CEO Joseph Papa said in a statement. “Under a new management team, we have strengthened our balance sheet and stabilized the company by simplifying our business and allocating resources more efficiently.”

Within the Bausch + Lomb/International segment, the Global Surgical segment posted $161 million in revenues in Q3-2017, a 4 percent increase over Q3-2016; the Global Vision Care segment reported $208 million, a 5 percent increase; Global Consumer Products posted revenues of $392 million, a decline of 2 percent; and Global Ophthalmology Rx reported revenues of $149 million, a decline of 8 percent.

Valeant updated its guidance for 2017, expecting full-year revenues in the range of $8.65 billion to $8.80 billion, down slightly from previous guidance of $8.70 billion to $8.90 billion.

Also, Valeant reported Nov. 6 that it gave back its Sprout subsidiary, maker of the female libido product Addyi, to the former owners for a 6 percent royalty on future sales of Addyi. Valeant acquired the unit for $1 billion in 2015.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022